SLC22A17

Across TCGA pan-cancer cohorts, SLC22A17 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SLC22A17 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SLC22A17 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC22A17 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM are the cancer types where SLC22A17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.783	0.620	.016	7	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

SLC22A17–GBM (DFS)

Open the GBM breakdown →